SIREN : 880935309
ILODERMA is a French company founded 6 years ago, specialized in the sector Activités des sièges sociaux. Based in TASSIN-LA-DEMI-LUNE (69160), this company of category PME shows in 2024 a revenue of 297 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-04-25
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 297 287 € | 28 478 € | 139 915 € | 148 803 € | 21 605 € |
| Net income | -624 431 € | -787 050 € | -530 757 € | -159 504 € | -106 543 € |
| EBITDA | -532 267 € | -807 659 € | -516 727 € | -151 794 € | -106 802 € |
| Net margin | -210.0% | -2763.7% | -379.3% | -107.2% | -493.1% |
In 2024, ILODERMA achieves revenue of 297 k€. Over the period 2020-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +92.6%. Vs 2023, growth of +944% (28 k€ -> 297 k€). After deducting consumption (5 k€), gross margin stands at 292 k€, i.e. a rate of 98%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -532 k€, representing -179.0% of revenue. Positive scissor effect: EBITDA margin improves by +2657.0 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -624 k€ (-210.0% of revenue), which will impact equity.
297 287 €
291 873 €
-532 267 €
-530 367 €
-624 431 €
-179.0%
The debt ratio (= Financial debt / Equity x 100) stands at 245%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 26%. The balance between equity and debt is satisfactory.
245.035%
26.179%
-178.084%
-1.722
32.1%
In 2024, the debt ratio of ILODERMA (245.03) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of ILODERMA (26.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of ILODERMA (-1.72) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 398.73. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
398.728
-22.665
In 2024, the liquidity ratio of ILODERMA (398.73) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of ILODERMA (-22.7x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 8 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 54 days. Excellent situation: suppliers finance 46 days of the operating cycle (retail model). Inventory turnover is 6 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 450 days of revenue, i.e. 371 k€ to permanently finance. Over 2020-2024, WCR increased by +220%, requiring additional financing.
371 246 €
8 j
54 j
6 j
450 j
Based on 103 transactions of similar company sales in 2024, the value of ILODERMA is estimated at 112 260 € (range 53 506€ - 226 728€). The price/revenue ratio is 0.38x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 103 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ILODERMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sièges sociaux
The revenue of ILODERMA in 2024 is 297 k€.
ILODERMA recorded a net loss in 2024.
The headquarters of ILODERMA is located in TASSIN-LA-DEMI-LUNE (69160), in the department Rhone.
The tax return of ILODERMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ILODERMA operates in the sector Activités des sièges sociaux (NAF code 70.10Z). See the 'Sector positioning' section above to compare the company with its competitors.